Navigating Bioequivalence: Why Formulation Matters for Emodepside Treatment

Veterinary Vertex

Content provided by AVMA Journals. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by AVMA Journals or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

2M ago 21:04

MP3•Episode home

Send us a text

When traditional dewormers fail against resistant hookworms, veterinarians may turn to emodepside as a last resort. But are all formulations created equal? Not according to recently published research.
Join us as Theresa Quintana and Drs. Jeba Jesudoss Chelladurai and Stephanie Martinez reveal critical findings about bioequivalence between different emodepside formulations. Their research demonstrates that the feline topical formulation, when given orally to dogs at 3 mg/kg, produces approximately three times higher peak concentrations and 2.4-2.8 times greater systemic exposure compared to the EU canine modified-release tablet at the same dose.
These findings carry significant clinical implications, particularly for dogs with MDR1 mutations lacking P-glycoprotein transport mechanisms. Without this protective system, emodepside can accumulate in the brain and cause neurotoxicity. The research team guides us through proper diagnostic confirmation of resistant hookworms, recommended treatment approaches, and crucial safety considerations before turning to this last-line therapy.
The conversation expands into formulation differences, bioavailability challenges, and practical clinical protocols. Teresa, Jeba, and Stephanie emphasize that clients must follow strict fasting guidelines before and after administration, as food dramatically enhances emodepside absorption and could potentially lead to toxicity with the already higher-concentration feline product.
Whether you're dealing with suspected resistant hookworms in your practice or simply want to understand the science behind bioequivalence and drug safety, this episode provides essential knowledge for evidence-based clinical decision-making. This episode centers around the intersection of parasitology, pharmacology, and clinical medicine and highlights why the details matter when it comes to drug formulations and routes of administration.

AJVR article: https://doi.org/10.2460/ajvr.25.01.0027

INTERESTED IN SUBMITTING YOUR MANUSCRIPT TO JAVMA ® OR AJVR ® ?

JAVMA ® : https://avma.org/JAVMAAuthors

AJVR ® : https://avma.org/AJVRAuthors
FOLLOW US:
JAVMA ® :

Facebook: Journal of the American Veterinary Medical Association - JAVMA | Facebook

Instagram: JAVMA (@avma_javma) • Instagram photos and videos

Twitter: JAVMA (@AVMAJAVMA) / Twitter

AJVR ® :

Facebook: American Journal of Veterinary Research - AJVR | Facebook

Instagram: AJVR (@ajvroa) • Instagram photos and videos

Twitter: AJVR (@AJVROA) / Twitter
JAVMA ® and AJVR ® LinkedIn: https://linkedin.com/company/avma-journals

Chapters

1. Introduction and Greenies Sponsor (00:00:00)

2. ] Fun Facts and Conclusion (00:19:08)

161 episodes

#Science #Fitness #Podcasting Education #Medicine #AVMA Journals